Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nasdaq  >  Mylan Inc    

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets

Mylan Inc. : Mylan Increases 2012 Guidance Range to $2.45 to $2.55 in Adjusted Diluted EPS

share with twitter share with LinkedIn share with facebook
share via e-mail
05/10/2012 | 01:35pm CEST

PITTSBURGH, May 10, 2012 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today announced that it has increased its guidance range for 2012 to $2.45 to $2.55 in adjusted diluted earnings per share. Mylan's previous guidance range for 2012 was $2.30 to $2.50 per share. All of Mylan's other 2012 guidance metrics remain unchanged.

Mylan CEO Heather Bresch commented: "As we have said previously, we expect 2012 to be the best year to date in Mylan's history. The increase in our guidance is a result of our continued strong operational performance."

Mylan also announced that its Board of Directors has approved the repurchase of up to $500 million of the Company's common stock in the open market.

Mylan Executive Chairman Robert J. Coury stated: "Given our current share price and the continued strong performance of our business, we believe that the repurchase represents an appropriate use of our capital and an opportunity to return value to our shareholders, while still maintaining significant financial flexibility for the right strategic opportunities."

This press release includes statements that constitute "forward-looking statements," including with regard to, among other things, the company's future operations, its earnings expectations, its share repurchase program, its growth targets and anticipated product launches. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: challenges, the effect of any changes in customer and supplier relationships and customer purchasing patterns; the ability to attract and retain key personnel; changes in third-party relationships; the impacts of competition; changes in economic and financial conditions of the company's business; and uncertainties and matters beyond the control of management These cautionary statements should be considered in connection with any subsequent written or oral forward-looking statements that may be made by the company or by persons acting on its behalf and in conjunction with its periodic SEC filings. In addition, please refer to the cautionary statements and risk factors set forth in the company's Quarterly Report on Form 10-Q for the period ended March 31, 2012, and in its other filings with the SEC. The forward-looking statements herein are qualified by those cautionary statements and risk factors. The company undertakes no obligation to update statements herein for revisions or changes after the date hereof. The share repurchase program would be financed with cash on hand and availability under the Company's revolving credit and receivables securitization facilities. The program would not require any waivers or other exemptions under the Company's credit facility or under its bond indentures. The repurchase program does not obligate the Company to acquire any particular amount of common stock and may be suspended without notice.

Mylan is a global pharmaceutical company committed to setting new standards in health care. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service a habit, do what's right, not what's easy and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,100 generic pharmaceuticals and several brand medications. In addition, we offer a wide range of antiretroviral therapies, upon which approximately one-third of HIV/AIDS patients in developing countries depend. We also operate one of the largest active pharmaceutical ingredient manufacturers and currently market products in approximately 150 countries and territories. Our workforce of more than 18,000 people is dedicated to improving the customer experience and increasing pharmaceutical access to consumers around the world. But don't take our word for it. See for yourself. See inside. mylan.com

SOURCE Mylan Inc.

© PRNewswire 2012
share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MYLAN INC
04/14MYLAN : EpiPen shortages seen in Canada, UK but U.S. supply intact
04/13Mylan in Talks to Acquire Merck KGaA's Consumer Health Business -Reuters
04/13MYLAN NV : Wired News - Mylan to Collaborate with Fujifilm Kyowa Kirin Biologics..
04/11MYLAN : Investor Day Highlights Durability of Mylan's Global Platform
04/11MYLAN : to Leverage its World-Class Scientific Platform to Develop a Novel Deliv..
04/11MYLAN : Partners with Fujifilm Kyowa Kirin Biologics to Commercialize Biosimilar..
04/10MYLAN : to Acquire the Global Marketing Rights to a Once-monthly Glatiramer Acet..
04/06MYLAN : Strengthens Its Capital Structure by Extending Its Debt Maturities with ..
03/28MYLAN : Introduces Symfi™ Triple Combo Once-Daily HIV Treatment in the U.S..
03/28MYLAN : and Biocon Receive Approvals from the European Commission and TGA Austra..
More news
News from SeekingAlpha
2015Mylan (MYL) Heather M. Bresch on Q4 2014 Results - Earnings Call Transcript 
2015Mylan Q4 revenues up 15%, Specialty up 38% 
2015Mylan (MYL) Q4 2014 Results - Earnings Call Webcast 
2015Mylan EPS in-line, beats on revenue 
2015Notable earnings after Monday?s close